menu
    • menu

    Company profile for SpliSense

    Pfanstiehl, a global leader in the manufacture of cGMP high purity, low endotoxin, low metals (HPLE-LM)TM injectable grade excipients.

    Virtual Booth

    Contact Supplier

    Global Pharma Healthcare: Setting the global benchmark in quality, innovation, and care

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.

    Virtual Booth

    Contact Supplier

    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    SpliSense is an Israel-based company focused on transformative RNA-based treatments. Our pioneering platform harnesses Antisense Oligonucleotides (ASOs) for treatment of genetic diseases such as Cystic Fibrosis. Our innovative approach targets unmet needs in genetic pulmonary diseases. SpliSense aims at targeting the root cause of the disease, to overcome specific genetic mutations and restore protein function.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    SpliSenseIsrael Flag
    Country
    Country
    Israel
    Address
    Address
    The Hebrew University of Jerusalem Edmond Safra Campus Givat Ram, Jerusalem
    Telephone
    Telephone
    +972-52-836-77-31
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://splisense.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/splisenseltd
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    SpliSense Reveals Phase 2 Success of SPL84 in Cystic Fibrosis
    SpliSense Reveals Phase 2 Success of SPL84 in Cystic Fibrosis

    03 Sep 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/splisense-reports-positive-results-from-phase-2-study-of-spl84-in-cystic-fibrosis-302544977.html

    PR NEWSWIRE
    03 Sep 2025
    Share Share
    SpliSense Gets FDA Fast Track For SPL84 In Cystic Fibrosis
    SpliSense Gets FDA Fast Track For SPL84 In Cystic Fibrosis

    30 May 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/splisense-receives-fda-fast-track-designation-for-spl84-for-the-treatment-of-cystic-fibrosis-302157595.html

    PR NEWSWIRE
    30 May 2024
    Share Share
    CF Foundation Provides Up to $8.5M to SpliSense to Support a Clinical Trial
    CF Foundation Provides Up to $8.5M to SpliSense to Support a Clinical Trial

    03 Apr 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240403502200/en

    BUSINESSWIRE
    03 Apr 2024
    Share Share
    SpliSense Announces FDA Clearance of IND App for Ph 2 Initiation of SPL84
    SpliSense Announces FDA Clearance of IND App for Ph 2 Initiation of SPL84

    03 Apr 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/splisense-announces-fda-clearance-of-investigational-new-drug-application-for-phase-2-initiation-of-spl84-for-the-treatment-of-cystic-fibrosis-302107114.html

    PR NEWSWIRE
    03 Apr 2024
    Share Share
    SpliSense Successfully Completed Phase 1 Study of SPL84
    SpliSense Successfully Completed Phase 1 Study of SPL84

    06 Sep 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/splisense-successfully-completed-phase-1-study-of-spl84-rna-based-therapy-for-the-treatment-of-cystic-fibrosis-301918897.html

    PR NEWSWIRE
    06 Sep 2023
    Share Share
    SpliSense begins Phase I/II trial of SPL84 for cystic fibrosis
    SpliSense begins Phase I/II trial of SPL84 for cystic fibrosis

    15 Dec 2022

    // CLINICALTRIALSARENA

    https://www.clinicaltrialsarena.com/news/splisense-trial-spl84-cystic-fibrosis/

    CLINICALTRIALSARENA
    15 Dec 2022
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search